PHILADELPHIA, Dec. 9, 2016 /PRNewswire-USNewswire/ — A platform of orthopedic device technologies developed by researchers from Temple University are moving one step closer to becoming viable options for repairing broken bones and orthopedic applications. OrthoMend Research, Inc., a start-up company from Philadelphia, PA., recently acquired the exclusive license for these novel absorbable bone fixation and regenerative repair technologies and plans to develop them for commercial use. The company has leased space within the University City Science Center.
“OrthoMend Research, Inc. has licensed exclusive commercial rights from Temple University for Nano-Diamond technology in bone fixation which has the potential to evolve current therapies to fix, repair and regenerate bones and orthopedic “drug delivery applications,” OrthoMend Research, Inc. CEO Joseph P. Connell said. “It is our desire to commercialize the technology to improve clinical outcomes, reduce costs and alleviate pain and suffering for our patients.”
“OrthoMend Research represents the important role startups have in our commercialization process by bringing together the inventors, technology and business leadership to advance this orthopedic device to patients in need,” said Stephen Nappi, associate vice president for technology commercialization and business development at Temple.
“We are very excited to begin our next phase by manufacturing and testing the devices. We plan to make considerable contributions to clinical outcomes and improve patient’s lives by repairing broken bones without leaving hardware behind in a patient’s body.” said Connell.
Peter Lelkes, chair of bioengineering and director of the Institute for Regenerative Medicine and Engineering at Temple is equally enthusiastic about the licensing agreement and the potential for collaborative research and development opportunities.
“The licensing of our invention to OrthoMend Research is an important milestone in our efforts to translate our basic research from the bench to the bedside and will, without a doubt, result in commercial products that will benefit patients around the globe,” Lelkes said.
About OrthoMend Research: OrthoMend Research, Inc. is an emerging Regenerative Orthopedic Device Company pioneering new technologies intended to revolutionize bone fixation after orthopedic, surgical and trauma situations. OrthoMend Research, Inc. is involved with commercializing technologies licensed from Temple University for an absorbable suite of bone fixation and drug delivery devices. We will develop, test and launch absorbable screws, pins and possibly plates to repair the millions of broken bones occurring each year. We are steadfast to be the leader in orthopedic devices delivering real-world technologies to impact the lives of those in need. For more information, visit www.orthomend.com
About Temple University’s Department of Bioengineering: Founded in January 2012, the Dept. of Bioengineering in the College of Engineering has grown significantly in the past four years to about 300 undergraduate students, nearly 50 graduate students, 11 core faculty members and two dozen affiliated faculty from across the entire university. The Department is the home of a first-rate, nationally and internationally recognized bioengineering research enterprise that is supported by extramural funds from NIH, NSF, DoD and others. Its newly renovated, state-of-the-art research facilities (ca. 20,000 square feet) attract graduate students, postdocs, visiting scientists and scores of undergraduate students who pursue exciting basic and translational bioengineering research.
News media contacts:
Joseph P. Connell, CEO, OrthoMend Research, Inc., 910-233-0806, email@example.com
SOURCE Temple University